Inventurus Knowledge Solutions Limited (IKS) AI Stock Analysis

• Market Cap: ₹223.77B
• Dividend Yield: N/A
• Average Volume (3M): 4.58K
• Price to Earnings (P/E): 37.8
• Beta (1Y): 0.48
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 7,530
• Sector: Services
• Sector Strength: N/A
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 10.70
• Shares Outstanding: 171,573,170
• 10 Day Avg. Volume: 2,488
• 30 Day Avg. Volume: 4,579
• PEG Ratio: 1.45
• Price to Book (P/B): 13.85
• Price to Sales (P/S): 9.31
• P/FCF Ratio: 84.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 41.82
• Revenue Forecast (FY): ₹32.00B

• Rating: 75 Outperform
• Price Target: ₹1,504.00 ▼(-10.12% Downside)
• Action: Upgraded Date: 10/29/25
• Date: Action: Upgraded 10/29/25

Inventurus Knowledge Solutions exhibits strong financial performance with robust revenue growth and profitability, contributing significantly to the overall score. Technical analysis indicates stable momentum, supporting a positive outlook. However, the absence of valuation metrics introduces some uncertainty, slightly tempering the overall score.

Positive Factors

High revenue growth

A multi-year CAGR above 40% indicates sustained demand for IKS's healthcare RCM services and rapid top-line scaling. Durable revenue growth supports reinvestment, widens client footprints, and enables operating leverage that can strengthen competitive position over a 2–6 month horizon and beyond.

Exceptional gross margins

Consistently >99% gross margins point to high value, low direct-cost service economics in IKS’s delivery model. Such structural margins indicate pricing power and strong unit economics in RCM services, supporting durable profitability and higher cash conversion even as revenue scales.

Strong cash generation & improved leverage

Operating cash flows consistently exceed net income and free cash flow has grown, while the balance sheet shows a ~59% equity ratio and falling debt-to-equity. This combination signals resilient cash conversion and improving financial flexibility to fund growth or absorb shocks over the medium term.

Negative Factors

Net debt volatility

Fluctuating net debt levels suggest periodic swings in liquidity or financing choices. That volatility can tighten flexibility during downturns, complicate longer-term capital planning, and raises the risk that short-term funding needs could divert cash from strategic investments or client-facing initiatives.

Variable investing & financing cash flows

Significant swings in investing and financing cash flows point to episodic capital deployment or debt adjustments. While they may reflect growth investments, they increase forecasting uncertainty and can pressure liquidity or leverage if growth does not translate to predictable operating cash generation.

Operating expense / EBIT headroom

Notable room to improve EBIT margins suggests operating cost structure can be optimized. Without margin expansion, scaling revenue may not proportionally boost operating profits, leaving the company exposed to margin pressure from client mix shifts or wage and technology cost inflation.

Inventurus Knowledge Solutions Limited Business Overview & Revenue Model

Company Description

Inventurus Knowledge Solutions Ltd. engages in the provision of coding and scribe services, and delivering medical transcriptions. It operates through its sole segment of Healthcare. The Healthcare segment represents providing focused cost and process optimization solutions to clients in healthcare industry. The company was founded on September 5, 2006 and is headquartered in Thane, India.

How the Company Makes Money

IKS makes money primarily by providing outsourced, healthcare-specific operational services—most notably revenue cycle management (RCM)—to healthcare organizations under contracted service arrangements. Revenue is earned through service fees for executing recurring processes (e.g., billing/claims workflows, collections support, and other RCM activities) on behalf of clients, generally structured as ongoing engagements rather than one-time deliveries. The company’s key revenue stream is therefore B2B services revenue from healthcare clients, typically tied to the scope and volume of work handled (such as accounts, claims, or transaction throughput) and/or contracted rates for dedicated teams and process delivery. Information on specific fee structures (e.g., percentage-of-collections vs. fixed-fee vs. per-transaction), detailed revenue mix by service line, and named partnerships is not available in the provided context; therefore: null.

Inventurus Knowledge Solutions Limited Financial Statement Overview

Summary

Inventurus Knowledge Solutions demonstrates robust financial health, characterized by strong revenue growth, high profitability margins, and efficient cash flow management. The company effectively manages its leverage, reflected in an improving balance sheet position. Nonetheless, some fluctuations in cash management and operating expenses present opportunities for further optimization.

Income Statement

Inventurus Knowledge Solutions shows strong revenue growth, with a CAGR of over 40% in the last three years. The company maintains high gross profit margins, consistently above 99%, indicating excellent cost management. Net profit margin and EBITDA margin are also robust, suggesting strong operational efficiency. However, the EBIT margin, while solid, shows room for improvement, indicating potential for optimizing operating expenses further.

Balance Sheet

The balance sheet reflects a favorable equity position, with an equity ratio of around 59%, highlighting financial stability. The debt-to-equity ratio decreased significantly from 2024 to 2025, indicating improved leverage management. Return on Equity (ROE) is strong at approximately 27%, showcasing effective use of shareholder funds. However, the company has experienced fluctuations in net debt levels, indicating potential volatility in cash management.

Cash Flow

The cash flow statement reveals solid free cash flow growth, supported by strong operating cash flows, which exceed net income consistently, indicating efficient cash conversion. The free cash flow to net income ratio remains healthy, underscoring the company's ability to generate cash after capital expenditures. However, investing and financing cash flows have shown variability, suggesting periods of significant capital investments and debt adjustments.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	27.63B	26.64B	18.17B	10.31B	7.64B	5.53B
Gross Profit	8.37B	26.63B	18.16B	5.05B	3.59B	2.47B
EBITDA	8.47B	8.09B	5.61B	3.89B	2.98B	1.82B
Net Income	5.33B	4.86B	3.70B	3.05B	2.33B	1.65B
Balance Sheet
Total Assets	0.00	30.52B	30.28B	9.88B	7.88B	5.86B
Cash, Cash Equivalents and Short-Term Investments	1.92B	2.19B	4.83B	5.23B	3.47B	2.24B
Total Debt	0.00	8.56B	13.11B	523.46M	651.92M	760.29M
Total Liabilities	-17.90B	12.62B	18.70B	1.60B	1.40B	1.29B
Stockholders Equity	17.90B	17.90B	11.58B	8.29B	6.47B	4.57B
Cash Flow
Free Cash Flow	1.06B	2.93B	1.77B	2.79B	2.22B	1.68B
Operating Cash Flow	1.19B	3.18B	2.10B	2.88B	2.33B	1.75B
Investing Cash Flow	1.42B	2.44B	-11.41B	-1.56B	-824.48M	-1.66B
Financing Cash Flow	-1.37B	-3.89B	7.80B	-1.52B	-585.10M	-365.65M

Inventurus Knowledge Solutions Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1673.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IKS, the sentiment is Negative. The current price of 1673.35 is above the 20-day moving average (MA) of 1455.77, above the 50-day MA of 1581.65, and above the 200-day MA of 1592.54, indicating a bearish trend. The MACD of -77.17 indicates Positive momentum. The RSI at 33.78 is Neutral, neither overbought nor oversold. The STOCH value of 54.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:IKS.

Inventurus Knowledge Solutions Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IKS	75 Outperform	₹223.77B	37.81	―	―	―	―
ECLERX	69 Neutral	₹148.29B	28.61	―	0.02%	17.83%	20.34%
CARTRADE	64 Neutral	₹78.63B	60.39	―	―	22.95%	284.54%
FSL	62 Neutral	₹157.21B	48.02	―	1.13%	25.92%	24.58%
IONEXCHANG	60 Neutral	₹49.54B	55.57	―	0.40%	11.56%	-2.78%
Sector *	55 Neutral	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%
HGS	55 Neutral	₹17.09B	12.17	―	1.51%	-2.43%	-100.43%

Inventurus Knowledge Solutions Limited Corporate Events

Inventurus Knowledge Solutions to Invest Up to USD 40 Million in Healthcare Tech Subsidiary

Inventurus Knowledge Solutions Limited has approved a further investment of up to USD 40 million in its wholly owned U.S. subsidiary Inventurus Knowledge Solutions Inc., which operates a care enablement platform for healthcare providers. The transaction, classified as a related-party deal but conducted on an arm’s length basis, is expected to strengthen the subsidiary’s business activities and deepen the parent company’s presence in healthcare technology services.

The board cleared the investment at a meeting on March 13, 2026, signaling confidence in the growth prospects of IKS Inc., which reported total income of about INR 6,997 million in FY 2024-25. This capital infusion should enhance the subsidiary’s operational capacity and could improve Inventurus Knowledge Solutions Limited’s competitive positioning in the fast-growing market for technology-enabled healthcare solutions.

Inventurus Knowledge Solutions Grants 600,000 Stock Options Under 2022 ESOP

Inventurus Knowledge Solutions Limited has granted 600,000 employee stock options under its 2022 Employee Stock Option Plan, following approval by the Nomination and Remuneration Committee on March 5, 2026. Each option is convertible into one equity share with a face value of Re. 1 at an exercise price of Rs. 1,331, set at or above the prior day’s market price on the National Stock Exchange, aligning the grant with Indian share-based benefit regulations.

The ESOPs can be exercised any time during continuous active employment after vesting, and the plan is administered through a trust structure, signaling a structured, long-term incentive framework for eligible employees. This move is likely aimed at strengthening employee retention and aligning staff interests with shareholder value, modestly expanding the company’s potential equity base while complying with SEBI’s latest disclosure and share-based compensation norms.

IKS Health Posts Double-Digit Q3 Growth on U.S. Platform Demand

The company posted Q3 FY26 revenue of INR 8,150 million, up 24% year on year, with EBITDA rising 40% and PAT climbing 41%, reflecting sustained expansion across existing and newly won provider clients. Management highlighted that tightened U.S. physician margins are accelerating adoption of IKS’s platform, while ongoing AI investments and partnerships with groups like StrideCare and VitalMD aim to reinforce profitability and operational efficiency gains.

Inventurus Knowledge Solutions Publishes Q3 FY26 Investor Presentation

Inventurus Knowledge Solutions Limited has released an investor presentation detailing its financial results for the quarter and nine months ended December 31, 2025, and has made the materials available to shareholders via its website. The disclosure, made under market listing regulations, aims to provide greater transparency to investors and other stakeholders, and will be disseminated through both the BSE and NSE platforms to support informed trading and engagement with the company’s financial performance.

Inventurus Knowledge Solutions Cancels January 20 Analyst and Investor Meet

Inventurus Knowledge Solutions Limited has notified the stock exchanges that its planned analyst and institutional investor meeting, previously scheduled for 20 January 2026, will not take place. The company cited unforeseen scheduling exigencies for the cancellation and formally communicated the change to stakeholders, expressing regret for any inconvenience caused and indicating that the notice is for information and record-keeping purposes.

Inventurus Knowledge Solutions Grants 46,000 ESOPs Under 2022 Plan

Inventurus Knowledge Solutions Limited has granted 46,000 employee stock options to eligible staff under its Employee Stock Option Plan 2022, as approved by the Nomination and Remuneration Committee on 24 December 2025. Each option is convertible into one equity share of face value Re 1 at an exercise price of Rs 1,749, aligned with the previous trading day’s market price on the National Stock Exchange, reinforcing the company’s use of equity-based incentives to retain and motivate employees while complying with SEBI’s share-based benefit regulations.